Crystal structure of a 3B3 variant - A broadly neutralizing HIV-1 scFv antibody

Protein Science

Volumn 18, Issue 12, 2009, Pages 2429-2441

  Clark, K Reed ^a,b   Walsh, Scott T R ^c  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

3B3; Broadly neutralizing antibody; Envelope protein gp120; HIV; Single chain variable fragment; X ray crystallography

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS ENVELOPE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73149107029     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.255     Document Type: Article

References (40)

1. Cohen J (2007) AIDS research. Did Merck's failed HIV vaccine cause harm? Science 318:1048-1049.
2. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR (2002) Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76:8769-8775.
3. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR (2009) Vector-mediated gene transfer ejenders long-lived neutralizing activity and protection against SIV infeciton in monkeys. Nat Med 15:901-906.
4. Haynes BF, Montefiori DC (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines 5: 579-595.
5. Burton DR, Barbas CF, III, Persson MA, Koenig S, Chanock RM, Lerner RA (1991) A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 88: 10134-10137.
6. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
7. Poignard P, Saphire EO, Parren PW, Burton DR (2001) gp120: biologic aspects of structural features. Annu Rev Immunol 19:253-274.
8. Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV, Jr, Parren PW, Burton DR (2003) A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol 77:6965-6978.
9. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, Dawson PE, Wilson IA, Burton DR (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 77:5863- 5876.
10. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
11. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR (2004) Comprehensive crossclade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78:13232-13252.
12. Barbas CF, III, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci USA 91: 3809-3813.
13. McHugh L, Hu S, Lee BK, Santora K, Kennedy PE, Berger EA, Pastan I, Hamer DH (2002) Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 277:34383-34390.
14. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA (2001) Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155-1159.
15. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PW, Burton DR, Scott JK, Wilson IA (2007) Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 crossreactive antibodies. J Mol Biol 369:696-709.
16. Barbas CF, III, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Cabezas E, Satterthwait AC, Sanz I, Burton DR (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230:812-823.
17. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578.
18. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR (2005) Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79:955-965.
19. Ruiz N, Kahne D, Silhavy TJ (2006) Advances in understanding bacterial outer-membrane biogenesis. Nat Rev Microbiol 4:57-66.
20. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40:658-674.
21. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF, III (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392-403.
22. Al-Lazikani B, Lesk AM, Chothia C (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273:927-948.
23. Kuroda D, Shirai H, Kobori M, Nakamura H (2009) Systematic classification of CDR-L3 in antibodies: implications of the light chain subtypes and the VL-VH interface. Proteins 75:139-146.
24. Burton DR, Stanfield RL, Wilson IA (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102:14943-14948.
25. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, Zhang MY, Pantophlet R, Martin L, Vita C, Burton DR, Dimitrov DS, Ji X (2004) Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43:1410-1417.
26. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
27. Zwick MB, Bonnycastle LL, Menendez A, Irving MB, Barbas CF, III, Parren PW, Burton DR, Scott JK (2001) Identification and characterization of a peptide that specifically binds the human, broadly neutralizing antihuman immunodeficiency virus type 1 antibody b12. J Virol 75:6692-6699.
28. Sundberg EJ, Mariuzza RA (2002) Molecular recognition in antibody-antigen complexes. Adv Protein Chem 61: 119-160.
29. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234: 946-950.
30. Pellequer JL, Chen S, Roberts VA, Tainer JA, Getzoff ED (1999) Unraveling the effect of changes in conformation and compactness at the antibody V(L)-V(H) interface upon antigen binding. J Mol Recognit 12:267-275.
31. Masuda K, Sakamoto K, Kojima M, Aburatani T, Ueda T, Ueda H (2006) The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity. FEBS J 273:2184-2194.
32. Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA (2003) Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Protein Sci 12:1960-1970.
33. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4:2411-2423.
34. Otiwinowski Z, Minor W,Processing of X-ray diffraction data collected in oscillation mode. In: Carter CWJ,Sweet RM, Eds. (1997) Methods in enzymology, Vol.276.New York:Academic Press, 307-326.
35. Zwart PH, Afonine PV, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, McKee E, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Storoni LC, Terwilliger TC, Adams PD (2008) Automated structure solution with the PHENIX suite. Methods Mol Biol 426:419-435.
36. Terwilliger TC (2003) SOLVE and RESOLVE: automated structure solution and density modification. Methods Enzymol 374:22-37.
37. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D 60:2126-2132.
38. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, III, Snoeyink J, Richardson JS, Richardson DC (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35 (Web Server issue): W375-W383.
39. Collaborative Computational Project, No. 4(1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D 50:760-763.
40. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797.